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Precis:  34 
Two new homozygous PTRF mutations associated with Congenital Generalized Lipodystrophy induce 35 
cellular maladaptative autophagy resulting in insulin resistance and altered adipocyte differentiation. 36 
37 
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Abstract 38 
 39 
Context: Mutations in PTRF encoding cavin-1 are responsible for congenital generalized 40 
lipodystrophy type 4 (CGL4) characterized by lipoatrophy, insulin resistance, dyslipidemia and 41 
muscular dystrophy. Cavin-1 cooperates with caveolins to form the plasma membrane caveolae, 42 
involved in cellular trafficking and signalling and in lipid turnover.  43 
Objective :We sought to identify PTRF mutations in patients with CGL and to determine their impact 44 
on insulin sensitivity, adipose differentiation and cellular autophagy. 45 
Design and patients : We performed phenotyping studies and molecular screening of PTRF in two 46 
unrelated families with CGL. Cellular studies were conducted in cultured skin fibroblasts from the two 47 
probands and from control subjects, and in murine 3T3-F442A preadipocytes. Knockdown of cavin-1 48 
or ATG5 was obtained by siRNA-mediated silencing. 49 
Results: We identified two new PTRF homozygous mutations (p.Asp59Val or p.Gln157Hisfs*52) in 50 
four patients with CGL4 presenting with generalized lipoatrophy and associated metabolic 51 
abnormalities. In probands' fibroblasts, cavin-1 expression was undetectable and caveolin-1 and -2 52 
barely expressed. Ultrastructural analysis revealed a loss of membrane caveolae and the presence of 53 
numerous cytoplasmic autophagosomes. Patients’cells also showed increased autophagic flux and 54 
blunted insulin signaling. These results were reproduced by PTRF knockdown in control fibroblasts 55 
and in 3T3-F442A preadipocytes. Cavin-1 deficiency also impaired 3T3-F442A adipocyte 56 
differentiation. Suppression of autophagy by siRNA-mediated silencing of ATG5 improved insulin 57 
sensitivity and adipocyte differentiation. 58 
Conclusions: This study showed that cavin-1 deficiency resulted in maladaptative autophagy which 59 
contributed to insulin resistance and altered adipocyte differentiation. These new pathophysiological 60 
mechanisms could open new therapeutic perspectives for adipose tissue diseases including CGL4. 61 
62 
 4 
INTRODUCTION 63 
 64 
Congenital generalized lipodystrophies (CGL) represent a group of rare monogenic disorders 65 
characterized by an overall defect in adipose tissue development associated with severe insulin 66 
resistance, diabetes, dyslipidemia and liver steatosis. CGL is a heterogeneous genetic disease, but the 67 
great majority of cases are due to biallelic mutations in either BSCL2 encoding seipin, a protein 68 
involved in adipogenesis and lipid droplet formation, or AGPAT2 encoding the enzyme 1-acyl-69 
glycerol-3-phosphate acyltransferase-ß involved in the biosynthesis of triglycerides and 70 
glycerophospholipids (1). A few cases of CGL have been shown to result from mutations in CAV1, 71 
encoding caveolin-1 (2,3) or from mutations in PTRF, encoding polymerase I and transcript release 72 
factor, also known as cavin-1. PTRF mutations are responsible for the association of generalized 73 
lipoatrophy and muscular dystrophy, categorized as congenital generalized lipodystrophy type 4 74 
(CGL4) (4-10).  75 
Both cavin-1 and caveolin-1 are required for the formation of caveolae, which are specialized 76 
omega-shaped microdomains of the plasma membrane involved in endocytosis, signal transduction, 77 
and lipid transport and metabolism (11,12). Cavin-1 is a scaffold protein present in numerous cell 78 
types, including myocytes, endothelial cells, fibroblasts and adipocytes, where caveolae are 79 
particularly abundant. Cavin-1 has a critical importance for caveolae assembly (11), recruiting 80 
caveolins into caveolae and preventing their degradation by the endolysosomal system (13). In 81 
addition, cavin-1 colocalizes with caveolin-1 and -2, hormone-sensitive lipase and perilipin-1 at the 82 
adipocyte lipid droplet surface, and contributes to the regulation of lipid droplet expandability (12,14-83 
18). Cavin-1 is also present in the cell nucleus, where it participates in transcription processes and 84 
regulation of cellular senescence (19).  85 
Few studies have investigated the cellular consequences of CGL4-linked cavin-1 mutations. 86 
They were shown to result in a secondary deficiency of caveolins, which could play an important 87 
pathophysiological role (2-4,7,8). Accordingly, cavin-1 knock-out in mice recapitulates the phenotype 88 
observed in caveolin-1 deficient mice, including lack of cellular caveolae, lipodystrophy and insulin 89 
resistance (20-22).  90 
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Macroautophagy – hereafter referred to as “autophagy” – is the main cellular pathway for 91 
lysosomal degradation of altered proteins and organelles. Autophagy plays a crucial role in protein 92 
quality control in a basal state, and contributes to cellular defense when activated in response to stress 93 
conditions (adaptative autophagy) (23). Importantly, autophagy has also been shown to regulate lipid 94 
metabolism, adipocyte differentiation and insulin sensitivity (24,25). Aberrant regulation of adipose 95 
tissue autophagy has been reported in obesity and diabetes (26). Interestingly, caveolin-1 suppression 96 
in mice has been shown to overactivate autophagy in stromal cells (22) and adipocytes (27). Caveolin-97 
1 was also demonstrated to regulate autophagy in lung and vascular endothelial cells (28,29). 98 
However, the role of cavin-1 in the regulation of autophagy and associated metabolic functions 99 
remains to be investigated. 100 
 In this study, we identified new PTRF mutations in two families with CGL and show that 101 
subsequent loss of cavin-1 expression led to autophagy upregulation, resulting in insulin resistance 102 
and altered adipocyte differentiation. These novel pathophysiological mechanisms could offer 103 
innovative therapeutic perspectives for this severe orphan disease and other adipose tissue diseases 104 
associated with maladaptative autophagy. 105 
 106 
SUBJECTS AND METHODS 107 
 108 
Subjects 109 
Two unrelated patients issued from consanguineous families originating from Egypt and from 110 
Switzerland, were referred to Saint-Antoine hospital (Paris, France) for CGL. Clinical, biological, 111 
molecular, and cellular studies of the probands and their relatives were performed after full informed 112 
consent according to legal procedures.  113 
 114 
Phenotype and genotype characterization 115 
Subjects underwent clinical evaluation and routine biological measurements, performed after an 116 
overnight 12-h fast. Serum adiponectin and leptin levels were determined by ELISA (Quantikine, 117 
R&D Systems, Oxford, UK). Genomic DNA was extracted from peripheral-blood leukocytes. The 118 
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entire coding region and splice junctions of genes involved in lipodystrophies (i.e. BSCL2, AGPAT2, 119 
CAV1, PTRF, LMNA, PPARG, AKT2, CIDEC, PLIN1) were amplified by PCR with specific primers 120 
in the two probands (primers sequences are available upon request). Purification of PCR products was 121 
performed on Sephadex columns and sequencing used Big Dye Terminator chemistry (Applied 122 
Biosystems). PTRF was also sequenced in the probands’ family members and in 100 unrelated control 123 
subjects. 124 
 125 
Cellular studies 126 
Primary fibroblast cultures were established from skin biopsies in the two probands and compared 127 
to those from two healthy women aged 20 and 33 (30). Murine 3T3-F442A preadipocytes were 128 
cultured and induced for adipocyte differentiation during 7 days as described (31). 129 
For mRNA silencing, cells were incubated for 6h with 100 pmoles of control (scrambled) siRNA (sc-130 
37007), or a pool of 3-5 specific siRNA targeting murine or human PTRF (sc-76294 and sc-76293) or 131 
ATG5 (sc-41446 and sc-41445) (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), in the 132 
provided transfection reagent. Fibroblasts were studied 4 days after mRNA silencing. 3T3-F442A 133 
preadipocytes were evaluated 3 days after mRNA silencing (D0, undifferentiated state), then 7 days 134 
after adipocyte differentiation (D7). 135 
Western blot analyses were performed on whole cell extracts using specific antibodies listed in 136 
Supplemental Table 1. Protein detection and semi-quantitative analysis of western blots versus beta-137 
actin were performed using ChemiGenius2 Bio-imaging system (Syngene, Cambridge, UK).  138 
Autophagy is characterized by the formation of double-membrane organelles known as 139 
autophagosomes, which surround targeted cytoplasmic materials. The trafficking of autophagosomes 140 
and then their fusion with lysosomes leads to the degradation of the sequestrated material (32). During 141 
this process, the cytosolic protein LC3-I is modified to a lipidated form, LC3-II, which associates to 142 
autophagosome membranes and is then submitted to the autophagic flux. We monitored autophagy as 143 
previously described, in the presence or not of the autophagic flux blocker bafilomycin A1 (B1793, 144 
Sigma-Aldrich) (100 nM for 4h), which inhibits the late phase of autophagy by preventing the fusion 145 
between autophagosomes and lysosomes (33). We measured the amount of p62/sequestosome-1, an 146 
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autophagy substrate degraded in lysosomes. We also evaluated the rate of conversion of LC3-I to 147 
LC3-II (LC3-II-to-LC3-I ratio), which correlates with autophagosome formation, and the levels of 148 
LC3-II, which is also degraded in lysosomes. 149 
To study insulin signaling, cells maintained for 24h in a serum-free medium were incubated or not 150 
with 50 nmol/L human insulin (#I9278, Sigma-Aldrich) for 8min. We evaluated the total protein 151 
expression of insulin receptor and of the signalling intermediates extracellular signal-regulated kinase 152 
(ERK) 1/2 and Akt as well as their phosphorylated activated forms (Supplemental Table 1).  153 
Adipocyte conversion of 3T3-F442A cells was assessed by the expression of adipocyte-specific 154 
proteins and by Oil red O-staining of intracellular neutral lipid stores, which was quantified at 520 nm 155 
after solubilization in 10% SDS and normalization to the amount of total proteins. 156 
For mRNA expression studies, total RNA was isolated from cultured fibroblasts using RNeasy kit 157 
(Qiagen, Courtaboeuf, France). cDNA was synthesized using random hexamers and AMV-RT 158 
(Promega, Madison, WI, USA) for 60min at 42°C. Real-time PCR was performed with specific 159 
primers (available upon request) using the FastStart SYBR Green I mix and the LightCycler detection 160 
system (Roche Diagnostics, Meylan, France). TATA box binding protein (TBP) was used for 161 
normalization. The relative expression of genes was calculated by the LightCycler Relquant program 162 
using comparative Ct method. 163 
Immunofluorescence studies were performed on fibroblasts grown on glass coverslips, after fixation 164 
in methanol at -20°C. DAPI (4’,6’-di-amidine-2-phenylindole dihydrochloride) was used for nuclear 165 
staining. Cells were visualized and images were acquired using Leica SP2 confocal microscope and 166 
software. 167 
Ultrastructural analysis by electronic microscopy was performed on cultured fibroblasts fixed in 168 
2.5% glutaraldehyde at 4°C. Cells were rinsed in PBS, post-fixed in 1% osmium tetroxide, dehydrated 169 
using graded alcohol series then embedded in epoxy resin. Semi-fine sections (0.5 µm) were stained 170 
with toluidine blue. Ultrathin sections (60 nm) were contrasted with uranyl acetate and lead citrate and 171 
examined using a JEOL 1010 electron microscope (JEOL, Tokyo, Japan) with an OSIS mega View III 172 
camera.  173 
Quantitative results, presented as mean ± SD, were statistically analyzed by non-parametric Mann-174 
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Whitney test using PRISM software (GraphPad Software, Inc, CA, USA). P values <0.05 were 175 
considered as significant.  176 
 177 
RESULTS 178 
 179 
Phenotype studies  180 
Proband-1 was a 32-year-old woman, born from consanguineous parents (first-cousins) of Sicilian 181 
origin. She presented with paucity of fat and muscular hypertrophy since birth and was diagnosed with 182 
generalized lipodystrophy and diabetes at age 12. Despite high doses of insulin (up to 2U/kg/day) 183 
associated with pioglitazone (30 mg/day), chronic hyperglycemia persisted (HbA1c: 8.8%) and was 184 
complicated by proliferative retinopathy. Acute pancreatitis linked to major hypertriglyceridemia 185 
occurred at age 16. The patient had also mild mental retardation diagnosed during early childhood and 186 
hypergonadotrophic hypogonadism, with primary amenorrhea and limited breast development (Tanner 187 
stage 3). Her height was 158 cm, her weight 48 kg (BMI: 19.2 kg/m2). Muscular strength was normal 188 
but she complained of cramps. Acanthosis nigricans was present on neck and axillar folds. Abdominal 189 
ultrasonography showed hepatomegaly, and liver steatosis was diagnosed at age 23 on histology. 190 
Cardiac examination (including echography and electrocardiogram) was normal. Biological 191 
measurements revealed high creatine kinase levels, high triglycerides and low HDL-cholesterol levels, 192 
low leptin and adiponectin levels and mild renal insufficiency. Her 60 year-old mother (BMI 21.9, 193 
normal physical examination) had type 2 diabetes since age 46. Her 62 year-old father and 35 year-old 194 
sister were described as asymptomatic, without lipodystrophy, muscular signs, diabetes, or 195 
dyslipidemia. They refused medical examination and molecular analyses. 196 
 197 
Proband-2 was a 13-year-old girl at examination. She was born from Egyptian consanguineous 198 
parents (first-cousins), with a low birth weight (2000g) at term after an uneventful pregnancy. She was 199 
diagnosed with generalized lipodystrophy at age 1, and mild mental retardation at age 10. Her height 200 
was 151 cm, her weight 40 kg (BMI: 17.5 kg/m2, Z-score: -0.47). Spontaneous menarche occurred at 201 
age 15 after a normal pubertal development. In addition to typical generalized lipoatrophy, she showed 202 
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generalized muscular hypertrophy, pseudoacromegaloid features (enlarged hands and feet, prominent 203 
eyebrows’ arches), axillar and cervical acanthosis nigricans, and liver hypertrophy. Cardiac 204 
examination was normal. Biological investigations revealed normal fasting glucose with high insulin 205 
levels, slightly elevated liver enzymes, very low levels of leptin and adiponectin, and very high serum 206 
creatine kinase, although she did not complain of any muscular symptoms. One of her four sisters died 207 
at 2.5 months from respiratory distress. Her two youngest sisters, 2 and 6 years-old, were described 208 
with congenital generalized lipoatrophy and muscle weakness, associated with achalasia in the older 209 
one. Her 36 year-old mother, 41 year-old father, and 11 year-old sister were asymptomatic and their 210 
physical examination was normal.  211 
 212 
The main clinical and biological characteristics of the probands and affected relatives are summarized 213 
in Table 1.  214 
 215 
Molecular studies  216 
PTRF sequencing in proband-1 revealed a homozygous c.176A>T transversion in exon 1, predicting a 217 
p.Asp59Val substitution in the highly conserved N-terminal leucine-rich domain of cavin-1 (Fig. 1). 218 
Her mother was heterozygous for the mutation. A homozygous transversion of the last nucleotide of 219 
exon 1 (PTRF c.471G>C), predicting a Gln-to-His substitution at codon 157, was detected in proband-220 
2 and her two lipodystrophic sisters. Direct sequencing of cDNA derived  from proband-2’ cultured 221 
skin fibroblasts showed that this mutation results in a splicing defect. The frameshift insertion of 143 222 
nucleotides from intron 1, followed by a premature codon stop in exon 2, predicted the synthesis of a 223 
mutated truncated protein (PTRF p.Gln157Hisfs*52) (Fig. 1). Proband-2’ asymptomatic parents and 224 
sister were heterozygous for the mutation. The family trees, sequence analyses and alignments are 225 
shown in Fig. 1. The two PTRF mutations were absent in 100 unrelated control subjects (50 of 226 
Caucasian and 50 of Egyptian origin) and in the 1000 Genome Project Database. The PTRF 227 
p.Asp59Val mutation was reported in the Exome Aggregation Consortium (ExAC) Database with an 228 
allelic frequency of 0.00001658, in the heterozygous but not the homozygous state (2 alleles among 229 
120646). This mutation was not submitted to ClinVar. It was predicted to be damaging by Polyphen-2, 230 
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SIFT and MutationTaster. The truncating mutation PTRF p.Gln157Hisfs*52 was not reported in 231 
ExAC. No pathological alteration was found in other lipodystrophy-related genes in the two probands 232 
(i.e. BSCL2, AGPAT2, CAV1, PTRF, LMNA, PPARG, AKT2, CIDEC, PLIN1). 233 
 234 
Cell studies 235 
PTRF-mutated fibroblasts from the two probands showed decreased number of caveolae and 236 
increased autophagic flux  237 
Cavin-1 protein was not detectable in fibroblasts from the two probands, as shown by western blotting 238 
and immunofluorescence microscopy (Fig. 2A,B). Cavin-1 mRNA expression was strikingly 239 
decreased in fibroblasts from proband-2 but was not modified in proband-1 as compared to control 240 
cells (data not shown), suggesting post-translational modifications leading to protein degradation in 241 
this case. Protein levels of caveolin-1 and caveolin-2 were decreased (Fig. 2A). Electronic microscopy 242 
showed, respectively, a decreased number and an absence of plasma membrane caveolae in fibroblasts 243 
from proband-1 and -2 as compared to control cells (Fig. 2C). In addition, an increased number of 244 
autophagic vacuoles was observed in fibroblasts from the probands. Some of these vacuoles, which 245 
displayed multimembranous structures, were identified as autophagosomes (Fig. 2D).  246 
To further characterize intracellular autophagy in PTRF-mutated vs control fibroblasts, we evaluated 247 
the conversion from soluble microtubules-associated light chain 3 protein (LC3-I) to vacuolar 248 
membrane-associated LC3-II, which correlates with autophagosome formation (34). 249 
Immunofluorescence detection of LC3 showed an increase in the number of LC3-positive bright 250 
puncta, depicting LC3-II associated with autophagosomes, in cells from probands as compared to 251 
controls (Fig. 2B). Western blot revealed increased LC3-II levels and LC3-II-to-LC3-I ratios, showing 252 
that the number of autophagosomes was increased, in patients' versus controls’ fibroblasts (Fig. 2E). 253 
The selective autophagy substrate p62, which is degraded by lysosomes when autophagy is activated, 254 
was decreased in patients' versus control cells, in favor of an enhanced autophagic flux (Fig. 2E). As 255 
expected, blockade of the autophagic flux by bafilomycin A1, which prevents the fusion between 256 
autophagosomes, endosomes and lysosomes (33), increased LC3-II-to-LC-I ratio and inhibited 257 
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substrate degradation as reflected by increased p62 levels, in both control and mutated fibroblasts 258 
(Fig. 2F).  259 
Taken together, these results show that patients’ fibroblasts with cavin-1 deficiency displayed 260 
decreased caveolae formation and increased autophagic flux.  261 
 262 
PTRF-mutated fibroblasts from the two probands displayed cellular insulin resistance, and 263 
siRNA-mediated PTRF knockdown in control fibroblasts recapitulated increased autophagy and 264 
insulin resistance 265 
We evaluated insulin-stimulated activation of the insulin receptor and the insulin signaling 266 
intermediates protein kinase B (PKB/Akt) and extracellular-regulated kinases (ERK1/2) in fibroblasts 267 
from the two patients and from control subjects. Insulin-induced activation of the signaling proteins 268 
was blunted in probands’ fibroblasts as compared to controls (Fig. 3A).  269 
To determine the involvement of cavin-1 deficiency in increased autophagy flux and insulin 270 
resistance, we performed siRNA-mediated silencing of PTRF in control fibroblasts. Efficient PTRF 271 
knockdown also led to a drastic reduction in caveolin-1 and -2 proteins (Fig. 3B), and activated the 272 
autophagic flux, as shown by an increase in LC3-II level and LC3-II-to-LC3-I ratio and a decrease in 273 
p62 level (Fig. 3C). In addition, PTRF knockdown reduced insulin-activated phosphorylation of Akt 274 
and ERK1/2 (Fig. 3D). 275 
These results demonstrated that cavin-1 deficiency activated autophagy and reduced insulin response 276 
in human fibroblasts. 277 
 278 
PTRF silencing in 3T3-F442A preadipocytes activated autophagy, induced insulin resistance and 279 
impaired adipocyte differentiation  280 
We then studied the effects of PTRF mRNA silencing in murine 3T3-F442A preadipocytes. Cells 281 
were evaluated 3 days after siRNA transfection, in the undifferentiated state (D0), and 7 days after 282 
induction of differentiation (D7). As observed in fibroblasts, PTRF silencing was associated with a 283 
decrease in caveolin-1 and caveolin-2 proteins, both at D0 (data not shown) and D7 of differentiation 284 
(Fig. 4A). PTRF knockdown also activated autophagy, as shown by increased LC3-II-to-LC3-I ratio 285 
 12 
and decreased p62 protein amount (Fig. 4A). In addition, insulin signaling, studied at D7 of 286 
differentiation, was blunted in cavin-1 deficient 3T3-F442A cells. PTRF silencing decreased insulin-287 
induced phosphorylation of insulin receptor β-subunit, Akt and ERK1/2, indicating cellular insulin 288 
resistance (Fig. 4B). Beside, PTRF knockdown significantly decreased the total amount of insulin 289 
receptor ß-subunit, which also represents a marker of mature adipocytes (1.27 ± 0.14 vs 0.66 ± 0.05 290 
arbitrary units (mean ± SD) in control and cavin-1 deficient 3T3-F442A cells, respectively, p=0.05). 291 
In accordance, adipocyte differentiation of 3T3-F442A cells, assessed by increased protein expression 292 
of key adipocyte transcription factors (C/EBP-α, PPARγ, SREBP-1c) and of the mature adipocyte 293 
marker fatty acid synthase (FAS) from D0 to D7, was impaired by PTRF knockdown (Fig. 4C). 294 
Finally, PTRF mRNA silencing decreased the ability of differentiating 3T3-F442A cells to store 295 
lipids, as indicated by decreased Oil red O-staining at D7 of differentiation (Fig. 4D).  296 
Therefore, in 3T3-F442A cells, cavin-1 knockdown was responsible for activation of autophagy, 297 
insulin resistance and impaired adipocyte differentiation. 298 
 299 
In PTRF-mutated fibroblasts from the two probands, suppression of autophagy by ATG5 300 
knockdown partially reversed cellular insulin resistance  301 
To further investigate the role of increased autophagy in PTRF knockdown-induced insulin resistance, 302 
we blocked the mRNA expression of ATG5, a key component of the molecular core machinery of 303 
autophagy (33), in fibroblasts from probands and controls. As expected, efficient ATG5 silencing 304 
reversed the overactivation of autophagic processes associated with cavin-1 deficiency, as shown by a 305 
decreased LC3-II-to-LC3-I ratio and an increased p62 amount in knocked-down versus untreated 306 
probands’cells (Supplemental Fig. 1A). We also observed that reducing autophagy in patients’ 307 
fibroblasts significantly increased the amount of p.Asp59Val mutated cavin-1 from proband 1, though 308 
it still remained lower than in control cells (Supplemental Fig. 1A). This suggests that overactivation 309 
of autophagy partially contributed to the posttranslational degradation of this cavin-1 mutant. ATG5 310 
silencing also increased insulin-induced phosphorylation of Akt and ERK1/2 in patients' fibroblasts 311 
(Fig. 5A). Importantly, ATG5 knockdown in control fibroblasts did not significantly alter the LC3-II-312 
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to-LC3-I ratio and p62 level (Supplemental Fig. 1A) and the insulin-mediated activation of Akt and 313 
ERK1/2 (Fig. 5A). 314 
 315 
In 3T3-F442A cells, suppression of autophagy by ATG5 siRNA-mediated silencing reversed 316 
PTRF knockdown-induced insulin resistance and altered adipocyte differentiation  317 
We then studied the effects of ATG5 mRNA silencing in murine 3T3-F442A preadipocytes subjected 318 
or not to PTRF knockdown prior to induction of differentiation. As expected, PTRF knockdown-319 
induced activation of autophagy was partially reversed by concomitant ATG5 silencing, the increased 320 
LC3-II-to-LC3-I ratio and decreased p62 levels being partly rescued at D7 of differentiation 321 
(Supplemental Fig. 1B and data not shown). As observed in patients’ fibroblasts, ATG5 knockdown 322 
in 3T3-F442A cells partly reversed the insulin resistance resulting from cavin-1 deficiency, as 323 
assessed by increased insulin-mediated phosphorylation of Akt and ERK1/2. Morever, ATG5 mRNA 324 
silencing increased both total protein level and insulin-mediated tyrosine phosphorylation of the 325 
insulin receptor ß-subunit in PTRF knockdown cells (Supplemental Fig. 1C). 326 
In addition, suppression of autophagy by ATG5 silencing prevented the decrease in C/EBPα, PPARγ, 327 
SREBP-1c and FAS proteins induced by cavin-1 deficiency in differentiating 3T3-F442A cells (Fig. 328 
5B). In accordance, it also improved the lipid storage capacity of cavin-1 deficient 3T3-F442A cells, 329 
evaluated by Oil red O-staining at D7 of differentiation (Fig. 5B).  330 
All together, these results showed that activation of autophagy induced by cavin-1 deficiency 331 
contributed to insulin resistance and impaired adipogenesis. 332 
 333 
DISCUSSION 334 
 335 
CGL are rare diseases of diverse molecular origin which are all characterized by the 336 
association of adipose tissue deficiency with metabolic complications usually observed in obese 337 
subjects (insulin resistance, hypertriglyceridemia and liver steatosis, among others), pointing to the 338 
critical role of adipose tissue in metabolic health. Thus, defective lipid storage in adipose tissue, due to 339 
disruption of adipogenesis and/or lipid droplet formation induced by AGPAT2 or BSCL2 mutations, 340 
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the main molecular alterations responsible for CGL, were shown to result in insulin resistance and 341 
associated metabolic dysfunction (1). In the present study, we assessed the cellular consequences of 342 
PTRF/cavin-1 deficiency, responsible for rare cases of CGL. We show that the lack of cavin-1 protein 343 
expression resulted in maladaptative autophagy, which triggered insulin resistance and altered 344 
adipocyte differentiation. These results add new insights into the complex relationships between 345 
adipose tissue and whole body metabolism. 346 
 We identified two new homozygous PTRF mutations, predicting a point mutation or a 347 
truncation in cavin-1 (p.Asp59Val or p.Gln157Hisfs*52 alterations), in two families with CGL4, 348 
characterized by generalized lipoatrophy, insulin resistance and/or diabetes, and high levels of creatine 349 
kinase with or without symptomatic muscular dystrophy. Both mutations led to a completely abolished 350 
cavin-1 protein expression in patients’cells.  351 
Although its physiological roles have not been completely deciphered, cavin-1 is recognized 352 
as a scaffold protein interacting with caveolin-1 both at the level of plasma caveolae and at the surface 353 
of adipocyte lipid droplet (11,14). Caveolin-1, involved in rare cases of CGL3, was shown to regulate 354 
the cellular process of autophagy (22, 27-29). Our results reveal, for the first time, that cavin-1 also 355 
contributes to the regulation of autophagy. 356 
We first confirmed, in fibroblasts from the two probands, that cavin-1 deficiency impaired 357 
caveolae formation and expression of caveolins (8,20). More importantly, we showed that 358 
patients’cells displayed intrinsic proximal insulin signaling defects, with alterations of insulin-359 
mediated activation of the insulin receptor and its downstream molecular targets, together with an 360 
increased autophagic flux. Recapitulation of these defects by cavin-1 knockdown, both in fibroblasts 361 
and in differentiating adipocytes, was consistent with the assumption that these alterations directly 362 
resulted from the lack of cavin-1. Interestingly, absence of caveolae, by leading to accumulation of  363 
glycosphingolipids into lysosomes, was shown to increase autophagy (12). In addition, insulin 364 
resistance and increased autophagy were previously described in caveolin-1 null mice (27,35). In 365 
accordance with these studies, we found that cavin-1 knockdown induced a decreased expression of 366 
the insulin receptor in adipocytes, which was rescued upon autophagy inhibition. Moreover, our 367 
results revealed that lack of cavin-1 also resulted in a global defect of insulin signaling pathways. 368 
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Interestingly, a decreased level of cavins induced by hypoxia was recently associated with impaired 369 
insulin signaling in adipocytes (36).  370 
Importantly, our results show that cavin-1 deficiency impaired adipocyte differentiation and 371 
that inhibition of autophagy by ATG5 knockdown rescued, at least partially, altered adipocyte 372 
differentiation and cellular insulin resistance. Taken together, our results strongly suggest that the 373 
metabolic defects induced by cavin-1 deficiency were mediated by a constitutive upregulation of 374 
autophagic flux. Cavin-1 could thus act as a physiological negative regulator of 375 
autophagy. Consistently, autophagy which is known to regulate adipocyte differentiation and insulin 376 
sensitivity (24,25),  has also been shown to contribute to lipid droplet breakdown (37). Interestingly, 377 
dysregulation of autophagy in adipose tissue could play an important role in the pathophysiology of 378 
obesity and diabetes (26).  379 
Autophagy is known to regulate adipocyte differentiation, adipose brown/white remodeling 380 
and insulin sensitivity (24,25). Suppression of autophagy by systemic Atg5 or adipose-specific Atg7 381 
knock-out in mice was previously shown to impair adipogenesis and induce lipoatrophy (24,37,38). 382 
However, increased autophagy due to the absence of cavin-1 (this study) or to caveolin-1 knock-out in 383 
mice (27) is also associated with impaired adipogenesis and lipoatrophy. In addition, autophagy was 384 
shown to be decreased (39), increased (40), or dysregulated (41) in adipose tissue from obese patients. 385 
This suggests that a finely regulated adaptative activation of autophagy is required for a proper 386 
homeostasis of adipose tissue. In accordance with our results, IGF1R mutations responsible for a 387 
subtype of SHORT syndrome with lipodystrophy and decreased insulin-induced Akt activation, were 388 
recently shown to activate autophagy (42). This suggests that Maladaptative autophagy could thus 389 
contribute to lipodystrophy and insulin resistance in several pathogenic situations. 390 
Although further studies are needed to decipher the precise underlying mechanisms linking 391 
cavin-1 deficiency and increased autophagy, our results show that maladaptative autophagy, triggering 392 
altered adipocyte differentiation and insulin resistance, could contribute to the pathophysiology of 393 
lipoatrophy and the associated metabolic dysfunctions in CGL4. Our study add further evidence for 394 
the role of lipid droplets, their coated proteins and/or caveolae proteins in dynamic cellular functions, 395 
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including autophagy (43), and could open new therapeutic options in the field of genetic 396 
lipodystrophies and other adipose tissue diseases associated with maladaptive autophagy. 397 
 398 
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FIGURE LEGENDS 407 
 408 
Figure 1. Proband-1 (A) and proband-2 (B) families and PTRF/cavin-1 molecular alterations.  409 
Patients with generalized lipodystrophy are depicted with black symbols and probands with arrows. 410 
PTRF sequences in control and probands are shown, with the consequences of each mutation on 411 
mRNA transcription and translation. Alignment of PTRF/cavin-1 aminoacid sequences includes the 412 
N-terminal leucine zipper domain from various species, with the conserved Asp59 residue in blue. In 413 
proband-2, PRTF sequencing revealed a homozygous c.471G>C transversion, affecting the last 414 
nucleotide of exon 1. Direct sequencing of cDNA derived from cultured skin fibroblasts showed that 415 
this mutation results in a splicing defect. The frameshift insertion of 143 nucleotides from intron 1, 416 
followed by a premature codon stop in exon 2, predicted the synthesis of a mutated truncated protein 417 
(p.Gln157Hisfs*52). 418 
 419 
Figure 2. Fibroblasts from patients with CGL4 showed lack of cavin-1 protein, decreased 420 
amount of plasma membrane caveolae and increased autophagic flux  421 
A- Protein expression of cavin-1 and its partners caveolin-1 and -2 were determined by western blot in 422 
control (Ctrl) and probands’fibroblasts (P1 and P2) as described in Methods. Beta-actin was used as an 423 
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index of the cellular protein level. A representative western blot (for each protein) is shown, with 424 
semi-quantitative analyses of western blots from experiments performed in triplicate (expressed as 425 
means ± SD). *: p< 0.05 as compared to control cells.  B- Representative photographs of 426 
immunofluorescence microscopy. Cavin-1 was revealed by red staining (absent in 427 
probands’fibroblasts), and LC3 by green signals, either diffuse (cytosolic form of LC3-I, control 428 
cells), or punctuated (LC3-II form associated with autophagosomes, probands’cells). Cell nuclei are 429 
stained in blue with DAPI. Scale bar: 10 µm. C, D- Fibroblasts were examined using electron 430 
microscopy. The number of plasma membrane caveolae (C, arrows) was decreased in fibroblasts from 431 
proband-1 and absent in fibroblasts from proband-2. The number of autophagosomes (D, arrows) was 432 
increased in probands’ cells (inset: magnification showing the characteristic double membrane of an 433 
autophagosome). Scale bar: 1 µm. E, F- Representative western blots showing the protein expression 434 
of LC3-I and LC3-II isoforms and of p62, which is degraded in lysosomes when autophagy is 435 
activated. Semi-quantitative analyses of western blots (expressed as means ± SD) show that LC3-II-to-436 
LC3-I ratio were increased in probands’fibroblasts as compared to control cells whereas p62 was 437 
decreased, showing activation of autophagy. (E) *: p< 0.05 as compared to control cells. (F) Increased 438 
autophagic flux in patients’cells was confirmed using bafilomycin, an inhibitor of the late phase of 439 
autophagy, which increased the LC3-II-to-LC3-I ratio and increased p62 in control and patients’cells. 440 
 441 
Figure 3. PTRF-mutated probands’ fibroblasts showed cellular insulin resistance, and PTRF 442 
knockdown in control fibroblasts recapitulated increased cellular autophagy and insulin 443 
resistance 444 
A- Insulin signaling activation was assessed in control (Ctrl) and probands’fibroblasts (P1 and P2). 445 
Representative western blots are shown, with quantification expressed as fold-stimulation by insulin of 446 
the activated/phosphorylated-to-total protein ratios (means ± SD). *: p< 0.05 as compared to control 447 
cells. IRβ: insulin receptor β-subunit, pTyr IRβ: phosphotyrosine-IRβ, pAkt: phospho-Ser473-Akt, 448 
pERK1/2: phospho-Tyr204-ERK1/2. B- Control fibroblasts were transfected or not with scrambled 449 
(scr) or PTRF-specific siRNA as indicated and assessed for protein expression of cavin-1, caveolin-1 450 
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and caveolin-2 as described in Methods. A representative western blot (performed in triplicate) is 451 
shown, with quantifications of the protein levels normalized to β-actin, expressed as means ± SD. *: 452 
p< 0.05 as compared to non-transfected cells. C- Western blot detection of LC3 protein isoforms LC3-453 
I and LC3-II, p62 and β-actin (loading control), in control fibroblasts transfected or not with 454 
scrambled or PTRF-specific siRNA as indicated. Semi-quantitative analyses of LC3-II-to-LC3-I ratios 455 
and p62 levels normalized to β-actin are expressed as means ± SD. *: p< 0.05 as compared to non-456 
transfected cells. D- Insulin signaling activation was assessed as in (A) in control fibroblasts 457 
transfected or not with scrambled or PTRF-specific siRNA as indicated. 458 
 459 
Figure 4. PTRF mRNA silencing in 3T3-F442A preadipocytes activated autophagy, induced 460 
insulin resistance and impaired adipocyte differentiation 461 
3T3-F442A cells were untransfected (none) or submitted to scrambled (scr) or PTRF-specific mRNA 462 
silencing as indicated. A- Representative western blots showing the effects of PTRF silencing on 463 
protein expression of cavin-1, caveolin-1 and caveolin-2, and on the conversion of LC3-I to LC3-II 464 
and the p62 protein amount, at D7 of adipocyte differentiation in 3T3-F442A cells. Quantifications of 465 
the protein levels normalized to β-actin are expressed as means ± SD. *: p< 0.05 as compared to non-466 
transfected cells. B- Insulin signaling activation was assessed at D7 by evaluating insulin-induced 467 
phosphorylation of insulin receptor β-subunit, Akt and ERK1/2, normalized to the total corresponding 468 
protein content. IRβ: insulin receptor β-subunit, pTyr IRβ: phosphotyrosine-IRβ, pAkt: phospho-469 
Ser473-Akt, pERK1/2: phospho-Tyr204-ERK1/2. C- Adipocyte differentiation of 3T3-F442A cells 470 
was evaluated by the protein expression of adipogenic factors (C/EBPα, PPARγ, SREBP-1c) and of 471 
the marker of mature adipocyte fatty acid synthase (FAS) at D0 and D7. A representative western blot 472 
and the quantifications of the proteins are shown, as described in (A) (means ± SD, *: p< 0.05 as 473 
compared to non-transfected cells). D- Oil red O-staining of intracellular stored lipids at D7 of 474 
differentiation was shown by fluorescence microscopy (cell nuclei are stained in blue with DAPI) and 475 
quantified with normalization to the total protein content as described in Methods.  476 
 477 
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Figure 5. Insulin resistance and impaired adipocyte differentiation induced by PTRF 478 
knockdown were partially rescued by ATG5 siRNA-mediated silencing  479 
A- Representative western blots showing the effects of ATG5 siRNA-mediated silencing on insulin-480 
mediated activation of Akt and ERK1/2 in control (Ctrl) and probands’ fibroblasts (P1 and P2). Cells 481 
were either untransfected or transfected with scrambled or ATG5-specific siRNA as indicated. 482 
Quantification was expressed as fold-stimulation by insulin of the activated/phospho-to-total protein 483 
ratios (means ± SD). *: p< 0.05 as compared to non-transfected cells from the same subject.  484 
pAkt: phospho-Ser473-Akt, pERK1/2: phospho-Tyr204-ERK1/2. 485 
B- Adipocyte differentiation of 3T3-F442A cells either untransfected, or submitted to scrambled, 486 
PTRF or to double PTRF and ATG5 siRNA silencing, was evaluated at D7 by protein expression of 487 
adipocyte markers and Oil red O-staining of intracellular stored lipids. Representative western blots 488 
and phase-contrast microscopy images are shown. The quantifications of the proteins levels 489 
normalized to β-actin are expressed as means ± SD. Oil red O-staining was quantified with 490 
normalization to the total protein content as described in Methods. Scale bar: 1 µm. *: p< 0.05 as 491 
compared to non-transfected cells.  492 
 493 
Supplemental Figure 1. Reversion of cavin-1 deficiency-mediated alterations by ATG5 494 
knockdown in patients’fibroblasts and PTRF-knocked down 3T3-F442A cells 495 
A- Autophagic flux was evaluated by LC3-II-to-LC3-I ratio and p62 levels in control and 496 
patients’cells, either untransfected, or transfected with scrambled or ATG5-specific siRNA as 497 
indicated. Quantifications of the protein levels normalized to β-actin are expressed as means ± SD. *: 498 
p< 0.05 as compared to non-transfected cells from the same subject. #: p< 0.05 as compared to non-499 
transfected cells control cells. 500 
B, C- 3T3-F442A cells either untransfected, or submitted to scrambled, PTRF or to double PTRF and 501 
ATG5 siRNA silencing as indicated, were studied at D7 of differentiation. Autophagic flux (B) and 502 
activation of insulin signaling (C) were evaluated. 503 
Representative western blots are shown, with quantifications expressed as protein levels normalized to 504 
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β-actin or fold-stimulation by insulin of the activated-to-total protein ratios (means ± SD).  505 
*: p<0.05 as compared to non-transfected cells. IRβ: insulin receptor β-subunit, P-Tyr IRβ: 506 
phosphotyrosine-IRβ, pAkt: phospho-Ser473-Akt, pERK1/2: phospho-Tyr204-ERK1/2. 507 
 508 
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Table 1 
Characteristics of patients with PTRF homozygous mutations. 
 
 Proband-1 Proband-2 Sister 1  of Proband-2 
Sister 2  
of Proband-2 
Reference 
ranges 
PTRF homozygous 
mutation p.D59V p.Q157HfsX52 p.Q157HfsX52 p.Q157HfsX52  
Age at examination (years) 32 13 6 2  
Sex  Female Female Female Female  
BMI (kg/m2) (Z-score in 
children)  19.2 17.5 (-0.47) 15.4 (0.13) 16.1 (-0.24)  
Lipodystrophy Congenital Generalized 
Congenital 
Generalized 
Congenital 
Generalized 
Congenital 
Generalized  
Acanthosis nigricans Neck, axillae Neck, axillae - No  
Mental retardation Mild Mild No No  
Muscular signs 
Generalized 
muscular 
hypertrophy, 
cramps 
Generalized 
muscular 
hypertrophy 
Calf 
hypertrophy, 
generalized 
muscle 
weakness 
Generalized 
muscle 
weakness 
 
Cardiac examination Normal  Normal Normal Normal  
Creatine kinase (IU/L) 308 1054 618 1202 15-95 
Fasting glucose (mmol/L) 9.5 4.5 4.2 4.3 4-5.6 
Fasting insulin  (mIU/L) Insulin-treated 16.3 9.2 4.5 2-10 
Triglyceride (mmol/L) 2.3 1.7 0.7 1.0 0.4-1.5 
Total cholesterol (mmol/L) 4.3 3.4 3.5 3.7 4.1-6.2 
HDL-cholesterol (mmol/L) 0.4 0.7 0.9 0.8 1.3-2.1 
Leptin (µg/L) 3.2 0.2 0.2 0.7 4-20 
Adiponectin (mg/L) 2.8 0.9 1.7 2.8 3.9-12.9 
Liver enzymes (AST/ALT) 
(IU/L) 32/34 43/53 44/60 43/52 5-35 / 5-35 
Liver examination 
Hepatomegaly 
and steatosis 
(histology) 
Hepatomegaly Hepatomegaly -  
 
BMI, body mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase 
BProband-2
I
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Mouse 47 KSDQVNGVLVLSLLDKIIGAVDQIQLTQAQLEERQA 82
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